Dexcom Expands Access to Glucose Biosensing With Pediatric Clearance for Stelo and New App Rollout Plans
DexCom, Inc. is broadening its push into preventive and personalized metabolic health with a new set of milestones for its over-the-counter glucose biosensing platform Stelo, including expanded pediatric clearance and the upcoming launch of a redesigned app experience in the United States. The announcements, unveiled during Aspen Ideas: Health, underscore the company’s strategy to move glucose monitoring beyond traditional diabetes management and into wider use for earlier intervention, lifestyle guidance and long-term health awareness. (DexCom Investors)
Dexcom said Stelo has now received FDA clearance for pediatric use, extending the product’s indication from adults ages 18 and older who are not using insulin to children ages 2 years and older who are not using insulin. The company also said it will begin rolling out a reimagined Stelo app experience in July for Apple iPhone and Android users in the United States, with plans to expand the platform internationally in stages beginning later this year. (DexCom Investors)
Taken together, the updates represent a significant step in Dexcom’s broader effort to make glucose biosensing more accessible to people earlier in the health continuum, including individuals and families seeking to better understand metabolic health before more serious disease develops.
Dexcom pushes glucose monitoring beyond traditional diabetes care
Dexcom has long been known as one of the leading companies in continuous glucose monitoring, particularly for people with diabetes who rely on real-time glucose data to help manage their condition. But in recent years, the company has increasingly positioned itself as a broader glucose biosensing company rather than solely a diabetes-device manufacturer, signaling ambitions to bring its technology to a much wider audience.
That shift is at the center of the company’s messaging around Stelo, its over-the-counter glucose biosensor designed for people who are not using insulin but want to track glucose patterns and gain more insight into how daily habits affect metabolic health. By eliminating the prescription requirement and simplifying the user experience, Dexcom is attempting to create a more approachable entry point for consumers who may have prediabetes, type 2 diabetes not treated with insulin, or a general interest in understanding how food, exercise, sleep and stress influence glucose levels. (Dexcom)
Jake Leach, Dexcom’s president and chief executive officer, framed the company’s latest announcements around a central idea: glucose matters to more people than those already diagnosed with diabetes, and understanding it earlier may help reduce the risk of more serious health complications later. In Dexcom’s view, widening access to glucose biosensing could support a more preventive model of care—one where people use real-time biological feedback to make healthier decisions before disease takes hold or worsens.
That theme is particularly relevant as healthcare systems, payers and technology developers increasingly talk about prevention, personalization and consumer-driven health management. Dexcom is clearly trying to position Stelo as part of that shift.
Pediatric clearance opens Stelo to a much younger population
One of the most notable developments announced by the company is the FDA clearance expanding Stelo’s indication to pediatric users. Earlier this month, the product received regulatory clearance for use in children ages 2 years and older who are not using insulin, broadening its original adult-only indication. According to Dexcom, the change could expand access to glucose insights for millions of families at a time when youth metabolic health concerns are becoming more prominent. (DexCom Investors)
The company pointed to a troubling backdrop for the decision. Rates of youth-onset type 2 diabetes have risen significantly over the past two decades, and broader metabolic health concerns are becoming more visible in children and adolescents. Dexcom cited data suggesting that metabolic syndrome affects about 4.5% of U.S. youth younger than 18, while public health projections indicate that the prevalence of type 2 diabetes among children could continue climbing sharply in the years ahead.
In that context, Dexcom sees Stelo as a tool that could help children, adolescents and their caregivers gain earlier visibility into glucose patterns and metabolic health trends. Because the device does not require insulin use and is intended to be more consumer-friendly than traditional prescription-based glucose monitoring systems, it could be used by families seeking more information about how diet, exercise, daily routines and other lifestyle factors are influencing a child’s glucose responses.
The pediatric expansion is also notable because it extends Dexcom’s vision of glucose awareness into a stage of life where long-term habits and health trajectories are often established. By giving younger users access to glucose data and insights, the company appears to be betting that earlier awareness can encourage healthier choices and potentially help families intervene sooner if metabolic warning signs begin to emerge.
Stelo app redesign aims to make glucose insights easier to understand
Alongside the pediatric label expansion, Dexcom announced that it will begin rolling out a fully reimagined Stelo app experience in July for iPhone and Android users in the United States. The redesign is intended to make glucose data easier for everyday users to interpret and act upon, especially those who may not have experience with continuous glucose monitoring or diabetes technology. (DexCom Investors)
The company has increasingly emphasized that raw glucose numbers alone are not enough to drive long-term engagement or behavior change. Instead, Dexcom wants Stelo to provide context—helping users understand how meals, physical activity, stress, sleep and other everyday behaviors influence glucose levels over time.
The redesigned app appears to be a major part of that strategy. Dexcom has described the new Stelo experience as more intuitive, personalized and insight-driven, with features designed to make metabolic health data less intimidating and more actionable for a broader consumer audience. The company has previously highlighted enhancements such as AI-enabled food logging, nutritional breakdowns for meals, daily insights, and personalized coaching-style summaries intended to help users identify patterns and connect their behaviors to their glucose responses. (DexCom Investors)
In practical terms, that means the app is being positioned not simply as a display tool for glucose readings, but as a digital health companion that translates sensor data into recommendations and learning moments. Dexcom believes this kind of user experience is essential if glucose biosensing is going to move beyond the traditional diabetes population and become a tool for broader metabolic awareness.
The company’s messaging suggests that the app redesign is intended to lower the barrier to entry for people who may be curious about their health but are not clinicians, not using insulin, and not familiar with interpreting glucose variability. By turning continuous data into simpler, more understandable insights, Dexcom is trying to make biosensing feel less like medical monitoring and more like a practical wellness tool.
Aspen Ideas: Health spotlight reinforces Dexcom’s preventive care narrative
Dexcom used the Aspen Ideas: Health stage to highlight not only the product milestones themselves, but also the larger conversation it wants to shape around glucose awareness and preventive care. The company said the importance of glucose understanding—and the need to broaden access to biosensing technology—would be central to a discussion featuring CEO Jake Leach, biochemist and author Jessie Inchauspé, widely known as the “Glucose Goddess,” and Ami B. Bhatt, MD, chief innovation officer of the American College of Cardiology.
The panel is focused on the role glucose plays in overall health, the potential for more personalized preventive care, and the system-level changes that may be needed to make innovative biosensing technologies available to more people. That setting is notable because it places Dexcom’s announcements within a broader public health and consumer health conversation, rather than limiting them to a device-industry or diabetes-specialist audience.
It also reflects how the company is trying to frame glucose monitoring as part of a more universal health discussion. Rather than talking only about insulin dosing or diabetes control, Dexcom is increasingly linking glucose insights to diet, sleep, cardiovascular risk, metabolic health and overall wellbeing. That approach aligns with the growing popularity of personalized health tracking and may help Dexcom reach consumers who are interested in wellness optimization as well as those at risk for metabolic disease.
International expansion planned as Dexcom builds Stelo’s footprint
Dexcom also reiterated that it intends to expand Stelo internationally, signaling that the platform is not just a U.S. experiment but a broader strategic growth initiative. According to the company, launches are expected to begin later this year and continue into 2027 across several international markets, including the United Kingdom, Australia, New Zealand and South Korea. (DexCom Investors)
Those markets could provide an important test of how glucose biosensing for non-insulin users resonates outside the United States, particularly in healthcare systems where approaches to preventive care, digital health adoption and reimbursement can vary widely. For Dexcom, international expansion also broadens the commercial opportunity for Stelo at a time when interest in metabolic health, consumer biosensing and personalized nutrition is rising globally.
The global rollout could also help Dexcom strengthen its competitive position as more companies look to bring continuous glucose data into wellness, preventive health and nontraditional diabetes care settings. By moving early and pairing the sensor with a consumer-focused app experience, Dexcom is trying to establish Stelo as a recognizable platform for people who want glucose insights without the complexity of conventional CGM programs.
Part of a broader strategy to redefine who glucose data is for
The Stelo milestones come amid a wider series of moves by Dexcom aimed at expanding continuous glucose monitoring into earlier-stage and nontraditional use cases. The company has recently emphasized clinical evidence supporting CGM use in people with type 2 diabetes who are not using insulin, as well as app upgrades and ecosystem enhancements intended to make its technology more useful across a wider range of health scenarios. (DexCom Investors)
That broader context matters because it shows the pediatric clearance and app relaunch are not isolated product updates. Instead, they appear to be part of a deliberate effort to redefine the role of glucose sensing—from a tool primarily associated with intensive diabetes management to a platform that supports prevention, self-awareness and personalized health decision-making.
For Dexcom, the commercial and clinical opportunity lies in convincing more people that glucose information can be relevant before they ever need insulin, before a formal diabetes diagnosis, or before complications emerge. If the company can make that case convincingly—and deliver a user experience that is simple enough for broader adoption—Stelo could become a key piece of Dexcom’s long-term growth strategy.
Dexcom’s latest announcements suggest the company is accelerating its attempt to bring glucose biosensing to a much broader population. With FDA clearance for pediatric use, a new Stelo app rollout beginning in July, and international expansion plans on deck, Dexcom is building out a platform designed not just for people managing diabetes, but also for families, consumers and patients seeking earlier visibility into metabolic health.
The success of that strategy will likely depend on more than sensor accuracy alone. It will require Dexcom to prove that people can meaningfully use glucose data to improve habits, identify risks earlier and stay engaged over time. The redesigned Stelo app is clearly meant to play a central role in that effort by turning complex biological data into more understandable, everyday guidance.
If Dexcom can execute on that vision, Stelo may become more than an over-the-counter glucose sensor. It could help establish glucose biosensing as a mainstream tool for preventive and personalized health—an outcome the company increasingly seems determined to pursue.
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
